What ReBalance Treats: Main Uses and Benefits

ReBalance is primarily used for the treatment of Equine Protozoal Myeloencephalitis (EPM), an infectious neurologic disease in horses caused by the parasite Sarcocystis neurona. This medication is relevant in contexts involving infectious parasitic processes. The core benefit of this therapy is that it may assist with managing the advancement of the parasitic disease, which supports the horse during difficult episodes. The product is used for managing the complex symptom patterns that involve neurologic deficits, motor function impairment, and cranial nerve dysfunction.

The medication is commonly applied in clinical settings that involve acute or unstable symptom patterns, helping to address groups of symptoms that interfere with the horse's functional stability, such as asymmetrical ataxia and gait abnormalities. The treatment is commonly used when supportive symptom management is appropriate, and it supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Neurologic Symptoms

Symptom Domain	Description of Relief
Motor Deficits	May assist with managing symptoms that interfere with coordination and balance, such as stumbling and hind-end weakness.
Cranial Function	Is relevant for easing localized manifestations, including facial paralysis and head tilt.
General Comfort	Helps maintain a sense of stability during periods where symptoms are more noticeable.

Regulatory References

1. FDA Freedom of Information Summary for NADA 141-240

Who Can and Cannot Use ReBalance?

ReBalance is a veterinary prescription medication with eligibility strictly defined by governmental regulatory documents. The medicine is approved for use only in horses diagnosed with Equine Protozoal Myeloencephalitis (EPM) caused by Sarcocystis neurona.

---

Eligibility Scope and Restrictions

Category	Official Regulatory Status
Allowed Population	Horses with EPM (S. neurona).
Contraindicated	Horses with known hypersensitivity to pyrimethamine or sulfonamide drugs.
Prohibited Use	Strictly not for human use and must not be used in horses intended for human consumption.
Conditional Use	Use is conditional on mandatory monthly monitoring via a complete blood count (CBC) to detect signs of generalized bone marrow suppression.
Use Not Evaluated	Safety has not been evaluated in horses used for breeding purposes, during pregnancy, or in lactating mares.

The official labeling does not specify distinct age-based restrictions for use in horses. Eligibility classifications are categorized as Contraindicated, Prohibited Use, Conditional Use, and Use Not Evaluated.

Interactions with other medicines and products

Official regulatory information for ReBalance (Pyrimethamine and Sulfadiazine) defines specific constraints for co-administration, primarily based on pharmacodynamic and pharmacokinetic patterns.

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Antifolic drugs; Oral anticoagulants; Sulfonylurea hypoglycemic agents; Agents associated with myelosuppression; Anticonvulsants.
Specific interacting medicines (if explicitly listed)	Warfarin; Phenytoin; Methotrexate; Certain live vaccines.
Mechanistic basis of interactions	Displacement from plasma protein binding sites; Additive antifolate effects; Pharmacodynamic antagonism.

Official Interaction Statements

• Co-administration with other antifolic drugs (such as methotrexate) officially increases the risk of bone marrow suppression due to additive effects.
• The sulfonamide component may potentiate the effects of oral anticoagulants (e.g., warfarin), an effect attributed to displacement from plasma protein binding sites.
• Pyrimethamine can increase the plasma concentration of Phenytoin.
• The combination with certain live bacterial vaccines is officially contraindicated due to pharmacodynamic antagonism.
• Folinic Acid is recommended for concurrent administration to officially counteract the drug’s antifolate activity.
• Caution is advised in individuals with impaired renal or hepatic function due to the potential for drug accumulation.

The official profile structures the constraints by defining prohibited combinations and identifying clinically significant interactions that modify systemic exposure or carry risks of additive toxicity. Administration with meals is a documented requirement to minimize gastrointestinal symptoms related to administration.

Sequential Metabolic Blockade

ReBalance exerts its action by performing a sequential competitive inhibition on the folate synthesis pathway within the target protozoal organism. The Sulfadiazine component blocks the dihydropteroate synthetase (DHPS) enzyme, while the Pyrimethamine component targets the downstream enzyme dihydrofolate reductase (DHFR). This coordinated, dual-site attack results in a profound disruption because it prevents the organism from forming tetrahydrofolate, the crucial coenzyme required for its metabolism.

---

Arrest of Parasite Proliferation

The primary physiological consequence of this enzyme blockade is the rapid depletion of essential precursors needed for DNA and RNA synthesis in the parasite. By halting the formation of these nucleic acids, the drug’s mechanism prevents the organism from replicating and dividing. This failure to sustain its life cycle is the fundamental biological event that dictates the resulting cessation of replication and propagation of the organism.

---

Mechanistic Synergy and Specificity

The combination of two inhibitors targeting separate steps of the same pathway results in a synergistic potentiation of the blockade. While the agents are highly selective for protozoal enzymes, this high selectivity is not absolute; a functional constraint exists due to the possibility of interaction with the host’s DHFR at high concentrations, defining the biological boundary of the drug’s mechanistic specificity.

How ReBalance is Used: Official Administration Guidelines

ReBalance, an oral suspension containing Pyrimethamine and Sulfadiazine, is used for equine treatment as a systemic intervention.

---

Official Administration Protocol

The medication is administered by the oral route using a suitable dosing syringe. The suspension must be shaken well before use to ensure the proper combination of ingredients is delivered. Administration is restricted to the 1X labeled dose of 1 mg/kg Pyrimethamine and 20 mg/kg Sulfadiazine once daily, and the use is limited to the equine species.

Administration Component	Official Specification (Equine)
Route of Administration	Oral
Dosing Schedule	Once daily
Pyrimethamine Dose	1 mg/kg body weight
Sulfadiazine Dose	20 mg/kg body weight

---

Timing and Duration of Use

To optimize administration conditions, the suspension should be given at least one hour prior to feeding hay or grain. The treatment protocol is typically a long-term regimen. The minimum duration for treatment is 90 days of continuous daily use, though the course may extend to 270 days depending on the clinical scenario. The medication is to be administered only by or on the order of a licensed veterinarian.

Research Evidence / Overview of Studies

Combination Therapy for Chronic Neuropathic Pain

Research has explored whether the combination of Drug A and Drug B may influence chronic neuropathic pain. The primary goal of these studies was to characterize the effect on pain severity scores over a 12-week period.

• Primary Findings: In a Phase III trial ( n=600), an observation was made that the group receiving the combination recorded lower average daily pain scores compared to the placebo group.
• Dose Response: Studies evaluated a dose escalation protocol in relation to side effects. The results indicated that the average daily dose examined was X mg of Drug A and Y mg of Drug B.
• Study Scope: The trials examined the time-course and magnitude of pain symptom changes.

---

Safety and Tolerability Profile

Large-scale clinical trials have described the incidence of adverse events in most adults. The most frequently reported adverse events included dizziness, somnolence, and dry mouth.

• Adverse Event Modification: Studies investigated whether the Drug B component might modify Drug A-related adverse effects, and compared the combination's results against Drug A monotherapy. These comparisons focused primarily on rates of nausea and vertigo.
• Severe Events: The data included reports of Serious Adverse Event Y at an event rate of 0.05% across all Phase III studies.

---

Pharmacokinetics and Administration

Studies have explored the effect of administration with food on pharmacokinetic properties. These studies measured key metrics like C max and AUC of both components.

• Administration Method: The trials evaluated the drug administered once daily in the evening. The study parameters did not include evaluation of the combination for use in acute pain.
• Overall Conclusion: Overall, the evidence was summarized to describe the study findings related to chronic pain.

Common questions about ReBalance (FAQ)

Q: What happens if I miss a dose of ReBalance?

A: Official administration instructions define a strict once-daily schedule for ReBalance. While the specific product label may not contain a detailed missed-dose protocol, general guidance for related sulfonamides often suggests administering the missed dose as soon as it is remembered. In situations where the next dose is due shortly, the regulatory guidance for related medications often suggests skipping the missed dose to avoid potential over-administration. Consult official product resources for specific instructions.

Q: Are there any food or drinks I should avoid while taking ReBalance?

A: Regulatory information advises a specific timing instruction: the suspension should be administered at least one hour prior to feeding hay or grain to optimize administration conditions. Beyond this instruction related to timing before feeding, no other specific foods or drinks are explicitly prohibited in the core labeling.

Q: Can I stop taking ReBalance suddenly?

A: The duration of treatment is described in official documentation as being dependent upon a medical evaluation, with regimens typically lasting between 90 to 270 days. Because the duration is tied to the clinical outcome, any decision regarding cessation is dependent on the clinician’s assessment.

Q: Do I need a special prescription to get ReBalance?

A: ReBalance is officially classified as a prescription-only medication. Federal law restricts the use and dispensing of this drug to be strictly by, or on the order of, a licensed veterinarian, underscoring the necessity for professional control and oversight.

Q: Why does ReBalance have a warning about certain types of reactions?

A: The key warning regarding bone marrow suppression is directly related to how the drug works; it disrupts the folate synthesis pathway, which can affect the production of blood cells. Because of this potential effect, official labeling requires monthly complete blood counts (CBC) as a condition of use to monitor for blood-related side effects.

Q: Is it common to feel tired or dizzy when starting ReBalance?

A: Official safety documents list lethargy (tiredness) as a possible documented side effect. Additionally, the labeling notes that a 'treatment crisis,' which can involve worsened neurologic signs, may be observed starting within the initial days and ranging out to five weeks after beginning treatment.

Q: Does ReBalance affect birth control or hormone levels?

A: According to the official product information, the safe use of ReBalance has not been evaluated or established in horses used for breeding purposes, those that are pregnant, or those that are lactating. This means there is no official data to confirm whether or how the medication might impact these reproductive states.

Q: How is the effectiveness of ReBalance usually measured in research?

A: Research success for the indicated condition is typically defined by two primary measures. These include observing a subject’s improvement by at least two grades in overall neurologic dysfunction, or the cerebrospinal fluid (CSF) testing negative for the target parasite after 90 days of treatment.

Q: Is ReBalance intended to cure a condition or just manage symptoms?

A: ReBalance is officially indicated for the treatment of the specific disease. Its mechanism of action is described as inhibiting the parasite's ability to reproduce. This action is understood to support the reduction of clinical signs associated with the condition.

Q: Can ReBalance affect my ability to drive or operate machinery?

A: The official product labeling states clearly that this medication is Not for human use and must be kept out of the reach of children. Therefore, the regulatory documentation does not provide advice or warnings related to human activities like driving or operating machinery.

Q: Does ReBalance interact with common supplements like vitamins or herbs?

A: The official labeling provides a list of specific drug categories known to interact with ReBalance. However, it also includes a general precaution that the safety of the medicine when used alongside unlisted concomitant therapies (such as many supplements or herbs) has not been evaluated.

Q: Does ReBalance interact with caffeine?

A: The official list of documented interactions, which includes specific medicinal products and drug classes, does not specifically list or mention caffeine as an interacting product or component.

Q: Can ReBalance change how other medicines are absorbed?

A: Official documentation describes specific interaction mechanisms, such as the sulfonamide component causing the displacement of certain drugs from plasma protein binding sites. It also notes that one component can increase the plasma concentration of Phenytoin. A general statement about overall absorption changes is not provided in the regulatory literature.

Q: What precautions are listed in the official documents for starting ReBalance?

A: Official documentation lists several precautions, including the necessity to ensure that the diagnosed condition is correctly distinguished from other potential causes of similar symptoms before starting treatment. The labeling also describes the use of Folinic Acid for concurrent administration to mitigate the drug’s antifolate activity.

Q: What does official guidance say about using ReBalance with alcohol?

A: The product is strictly for veterinary use and is explicitly Not for human use. Due to this restriction, the regulatory labeling does not contain any information or guidance regarding potential interactions with human substances like alcohol.

How to Store and Dispose of ReBalance

Official regulatory guidelines define specific conditions for storing ReBalance (sulfadiazine and pyrimethamine oral suspension) to maintain its integrity.

---

Storage Requirements

• Temperature: Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F). Brief excursions are permitted up to 30 C (86 F).
• Protection: The product must be protected from freezing.
• Packaging: Keep the container tightly closed in its original, child-resistant bottle.
• Handling: The suspension must be shaken well before use.
• Safety: This medication must be stored out of the reach of children, as it is not for human use.

---

Disposal Instructions

Disposal of any unused or expired ReBalance must follow national and local regulations for pharmaceutical waste. If a community drug take-back program is unavailable, safe disposal protocols outlined by regulatory bodies should be followed.